Table 4.

Univariate and multivariate analyses of clinicopathologic factors affecting disease-free survival and overall survival rate in peripheral blood

Clinicopathologic variableDisease-free survivalOverall survival
No. of patientsUnivariate analysis HR (CI)Multivariate analysisNo. of patientsUnivariate analysis HR (CI)Multivariate analysis
Relative risk (CI)PRelative risk (CI)P
Age (years)
    552330.98 (0.58-1.67)2370.55 (0.22-1.32)
    >55210215
Menopause
    Pre1650.86 (0.47-1.49)1670.21 (0.03-0.72)0.26 (0.04-0.94)0.039*
    Post278285
Tumor stage
    Tis-12260.60 (0.33-1.04)2260.61 (0.22-1.52)
    T2-4217226
Lymphatic invasion
    Present1722.08 (1.22-3.70)1.20 (0.65-2.27)0.561791.85 (0.78-4.55)
    Absent271273
Lymph node metastasis
    Present1703.60 (2.04-6.67)2.63 (1.32-5.43)0.0055*1773.97 (1.61-11.17)1.58 (0.63-4.51)0.34
    Absent273275
Venous invasion
    Present293.64 (1.23-8.33)2.76 (0.92-6.67)0.07294.00 (0.62-15.02)
    Absent414423
Distant metastasis
    Present095.32 (0.83-19.23)
    Absent443443
ER
    Present3180.49 (0.29-0.84)0.69 (0.34-1.41)0.33220.27 (0.11-0.64)1.50 (0.45-4.47)0.49
    Absent125130
PgR
    Present2450.55 (0.32-0.93)0.71 (0.36-1.43)0.352490.21 (0.07-0.54)0.18 (0.04-0.68)0.011*
    Absent198203
Her2 score
    0-12850.42 (0.25-0.72)0.69 (0.38-1.24)0.212920.47 (0.19-1.14)
    2-3158160
Recurrence
    Present565919.08 (5.26-33.33)2075<0.0001*
    Absent387393
CD47 expression
    High2211.57 (0.79-3.03)2261.10 (0.30-3.22)
    Low222226